MAXIM

• Research type

  Research Study

• Full title

  A Phase II Trial of Metformin and Axitinib in BRAF Mutated Advanced Melanoma

• IRAS ID

  71190

• Contact name

  James Michael George Larkin

• Eudract number

  2011-001793-26

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  Preliminary clinical evidence has shown that melanomas carrying a BRAF mutation can be targeted with drugs such as PLX4032 with significant tumour shrinkage occurring in up to 80% of cases. Resistance to drugs such as PLX4032 is inevitable however and other strategies are needed. Professor Richard Marais at the ICR has shown in the laboaratory that combining the diabetes drug metformin with a drug that attacks blood vessels in tumours can be a very effective treatment for melanoma with a BRAF mutation and the MAXIM study will be investigating this in patients with melanoma.

• REC name

  London - Brent Research Ethics Committee

• REC reference

  11/LO/1090

• Date of REC Opinion

  9 Sep 2011

• REC opinion

  Further Information Favourable Opinion